{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:06:48Z","timestamp":1779692808334,"version":"3.53.1"},"reference-count":52,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000369","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T16:46:47Z","timestamp":1069346807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interferon for acute hepatitis C"],"prefix":"10.1002","volume":"2010","author":[{"given":"Robert P","family":"Myers","sequence":"first","affiliation":[{"name":"AHFMR Clinical Investigator; Director, Viral Hepatitis Unit; University of Calgary Calgary Canada AB T2N 4N1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Regimbeau","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier Pitie-Salpetriere; Service d`Hepatol-Gastroenterologie; 47-83 boulevard de L\u00b4Hopital Paris Cedex 13 France 75651"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Thevenot","sequence":"additional","affiliation":[{"name":"Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[{"name":"Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Claude Huriez, 2\u00e8me etage Est; Service d'H\u00e9patogastroent\u00e9rologie; Avenue Mivchel Polonovski CHRU Lille France F- 59037"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Opolon","sequence":"additional","affiliation":[{"name":"Groupe d`Hospitalier Pitie-Salpetriere; Service d'H\u00e9pato-Gastro-Ent\u00e9rologie; 47-83 boulevard de l\u00b4Hopital Paris Cedex 13 France 75651"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Zarski","sequence":"additional","affiliation":[{"name":"Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Poynard","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier Pitie-Salpetriere, Paris, France; Service d'Hepato-Gastroenterologie; 47-83 boulevard de l'Hopital Paris Cedex 13 France 75651"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,10,23]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD000369-BIB0001|cit1","first-page":"181","article-title":"Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial","volume":"30","author":"Calleri","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0168-8278(94)80246-7","article-title":"A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C","volume":"21","author":"Hwang","year":"1994","journal-title":"J Hepatol"},{"issue":"1","key":"10.1002\/14651858.CD000369-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.1840190105","article-title":"A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C","volume":"19","author":"Lampertico","year":"1994","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD000369-BIB0004|cit4","first-page":"409","article-title":"A report on therapy of interferon alfa 2b in patients with acute hepatitis C","volume":"32","author":"Li","year":"1993","journal-title":"Chung Hua Nei Ko Tsa Chih"},{"issue":"8772","key":"10.1002\/14651858.CD000369-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0140-6736(91)91774-O","article-title":"Resolution of acute hepatitis C after therapy with natural beta interferon","volume":"338","author":"Omata","year":"1991","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.1840150504","article-title":"Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial","volume":"15","author":"Viladomiu","year":"1992","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD000369-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/978-4-431-68255-4_157","article-title":"Outcome of acute hepatitis C and role of alpha interferon therapy","volume-title":"Viral Hepatitis and Liver Disease","author":"Alberti","year":"1994"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD000369-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1136\/gut.34.2_Suppl.S141","article-title":"Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B\/type C hepatitis after transfusion","volume":"34","author":"Colombo","year":"1993","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD000369-BIB0009|cit9","first-page":"1847","article-title":"Interferon therapy for acute hepatitis C; changes in serum markers associated with HCV and clinical effects","volume":"52","author":"Fukui","year":"1994","journal-title":"Nippon Rinsho"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/0016-5085(92)91205-I","article-title":"Interferon alfa in acute posttransfusion hepatitis C: a randomized, controlled trial","volume":"103","author":"Genesca","year":"1992","journal-title":"Gastroenterology"},{"issue":"4 Pt. 2","key":"10.1002\/14651858.CD000369-BIB0011|cit11","first-page":"275A","article-title":"A trial of interferon therapy beta 1a for 4 weeks for therapy of acute hepatitis C (Abstract)","volume":"24","author":"Lee","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD000369-BIB0012|cit12","first-page":"596","article-title":"Treatment of posttransfusion non-A, non-B acute and chronic hepatitis with human fibroblast beta-interferon: a preliminary report","volume":"84","author":"Ohnishi","year":"1989","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1002\/14651858.CD000369-BIB0013|cit13","first-page":"1041","article-title":"Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status","volume":"86","author":"Ohnishi","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/14651858.CD000369-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/978-4-431-68255-4_156","article-title":"A randomized, controlled trial of interferon-beta treatment for acute hepatitis C","author":"Omata","year":"1994","journal-title":"Viral Hepatitis and Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD000369-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF01716714","article-title":"The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha","volume":"22","author":"Palmovic","year":"1994","journal-title":"Infection"},{"issue":"3","key":"10.1002\/14651858.CD000369-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0016-5085(94)90130-9","article-title":"Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group","volume":"107","author":"Takano","year":"1994","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000369-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1136\/gut.34.2_Suppl.S130","article-title":"Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis","volume":"34","author":"Tassopoulos","year":"1993","journal-title":"Gut"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD000369-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1007\/BF02087880","article-title":"High dose interferon alpha 2b treatment prevents chronicity in acute hepatitis C. A pilot study","volume":"41","author":"Vogel","year":"1996","journal-title":"Dig Dis Sci"},{"issue":"27","key":"10.1002\/14651858.CD000369-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJM199212313272702","article-title":"The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team","volume":"327","author":"Alter","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD000369-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.510310332","article-title":"The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States","volume":"31","author":"Armstrong","year":"2000","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD000369-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/BF02088245","article-title":"Interferon as treatment for acute hepatitis C. A meta-analysis","volume":"41","author":"Camma","year":"1996","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1002\/14651858.CD000369-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0168-8278(97)80451-5","article-title":"The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis","volume":"26","author":"Camma","year":"1997","journal-title":"J Hepatol"},{"issue":"22","key":"10.1002\/14651858.CD000369-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD000369-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods of combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Stat Med"},{"key":"10.1002\/14651858.CD000369-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Simonian","year":"1986","journal-title":"Controlled Clin Trials"},{"issue":"6","key":"10.1002\/14651858.CD000369-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199208063270601","article-title":"The declining risk of post-transfusion hepatitis C virus infection","volume":"327","author":"Donahue","year":"1992","journal-title":"N Engl J Med"},{"issue":"5464","key":"10.1002\/14651858.CD000369-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.288.5464.339","article-title":"The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies","volume":"288","author":"Farci","year":"2000","journal-title":"Science"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0168-8278(05)80358-7","article-title":"Hepatitis C viremia following clinical resolution of acute hepatitis C","volume":"20","author":"Giuberti","year":"1994","journal-title":"J Hepatol"},{"issue":"11","key":"10.1002\/14651858.CD000369-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD000369-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1002\/14651858.CD000369-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","article-title":"Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy","volume":"127","author":"Marcellin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1002\/14651858.CD000369-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD000369-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/jhep.2001.22112","article-title":"Acute hepatitis C","volume":"33","author":"Orland","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD000369-BIB0035|cit35","first-page":"820","article-title":"Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response","volume":"19","author":"Pagliaro","year":"1994","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD000369-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0197-2456(85)90103-5","article-title":"The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods","volume":"6","author":"Poynard","year":"1985","journal-title":"Controlled Clin Trial"},{"key":"10.1002\/14651858.CD000369-BIB0037|cit37","first-page":"315","article-title":"Evaluation of the methodological quality of randomized therapeutic trials","volume":"17","author":"Poynard","year":"1988","journal-title":"Presse Med"},{"issue":"4","key":"10.1002\/14651858.CD000369-BIB0038|cit38","first-page":"778","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effect of dose and duration","volume":"24","author":"Poynard","year":"1996","journal-title":"Hepatology"},{"issue":"9138","key":"10.1002\/14651858.CD000369-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD000369-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hep.510310131","article-title":"Is an \"a la carte\" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group","volume":"31","author":"Poynard","year":"2000","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C","volume":"34","author":"Poynard","year":"2001","journal-title":"J Hepatol"},{"issue":"5","key":"10.1002\/14651858.CD000369-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1445-5994.1997.tb00985.x","article-title":"Interferon therapy for aute hepatitis C viral infection - a review by meta-analysis","volume":"27","author":"Quin","year":"1997","journal-title":"Aust NZ J Med"},{"issue":"8","key":"10.1002\/14651858.CD000369-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM198702193160806","article-title":"Meta-analysis of randomized controlled trials","volume":"316","author":"Sacks","year":"1987","journal-title":"N Engl J Med"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD000369-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1002\/hep.510260704","article-title":"Natural history of hepatitis C","volume":"26","author":"Seeff","year":"1997","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD000369-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-132-2-200001180-00003","article-title":"45-year follow-up of hepatitis C virus infection in healthy young adults","volume":"132","author":"Seeff","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1002\/14651858.CD000369-BIB0046|cit46","first-page":"48","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update","volume":"8","author":"Thevenot","year":"2001","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1002\/14651858.CD000369-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0168-8278(91)90814-R","article-title":"Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials","volume":"13","author":"Tine","year":"1991","journal-title":"J Hepatol"},{"issue":"3","key":"10.1002\/14651858.CD000369-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.510290311","article-title":"Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection","volume":"29","author":"Vilano","year":"1999","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000369-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0168-8278(99)80399-7","article-title":"Treatment of acute hepatitis C virus infection","volume":"31","author":"Vogel","year":"1999","journal-title":"J Hepatol"},{"issue":"2","key":"10.1002\/14651858.CD000369-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.510300203","article-title":"Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group","volume":"30","author":"Ware","year":"1999","journal-title":"Hepatology"},{"issue":"23","key":"10.1002\/14651858.CD000369-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD000369-BIB0052|cit52","first-page":"48","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update","volume":"8","author":"Thevenot","year":"2001","journal-title":"J Viral Hepat"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:51:59Z","timestamp":1779691919000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000369"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2001,10,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000369","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,23]]}}}